Sage Bionetworks Commons Congress 2012


April 20 - 21, 2012

Previews


Looking Back at Three Years of Sage Commons Congress

Stephen H. Friend, President and Director of Sage Bionetworks, looks back at the last three years of the Sage Commons Congress.

The Importance of Third Parties in Drug Development

Kathy Giusti, founder and CEO of the Multiple Myeloma Research Foundation, discusses the importance of the role of trusted third party disease foundations in drug development.

Foldit: Crowdsourcing Protein Folding

Adrien Treuille from Carnegie Mellon University presents a game he co-created called Foldit. Foldit is a game designed to crowd source the science of protein folding.

Why Start a Federation for Disease Research?

Justin Guinney, a research scientist for Sage Bionetworks, discusses the motivation for starting the Sage Federation, which aims to promote inter-lab collaboration.

Translational Research Is Not a Linear Process

The Column Group Managing Partner Richard Klausner points out the problem with the standard model of translational medicine as it is practiced today.

Clinical Trials Can Miss Obvious Solutions

Jamie Heywood, co-founder of PatientsLikeMe, shows the flaws of relying solely on clinical trials for medical treatment because other methods can optimize interventions.

Competition Creates a Marketplace for Innovation

Chitra Krishnan of Ashoka describes how the competition model of funding social innovation can be applied to the biomedical industry.

Pushing Back on Current Pre-Competitive Boundaries

Anthony Ford-Hitchinson presents his tables findings of pushing back on current pre-competitive boundaries in the breakout groups for ‘Redefining How We Build Better Maps of Disease’.

John Wilbanks: Rethinking Science Funding

Director of Sage Bionetworks John Wilbanks examines the epistemology of science funding. Wilbanks explains most science funding goes into 'known knowns' because of the fear of undesired outcomes.

Challenge for FDA Regulators in a Global Market

Vicki Seyfert-Margolis of the FDA points to the increasing amount of imported products that the agency must regulate and the challenge of handling so much data.

Cancer Genomics Will Lead the Way to Personal Genomics

David Haussler, Director of the Center for Biomolecular Science & Engineering at the University of California, Santa Cruz, discusses the importance of cancer research and the impact that cancer genomics will have on personal genomics.

Big Data Leads to a Network-Driven View of Biology

Eric Schadt describes the vast amounts of data that have come into existence in the digital age and how it is has changing our view of biological systems.

Governance of Human Data in Synapse

Lara Mangravite, Sr. Scientist of Systems Biology at Sage Bionetworks, explains how Synapse software will analyze human data.

Larry Lessig: Two Sides in the Battle of Copyright

Harvard professor and author Larry Lessig details the opposing sides in the battle over copyright law, but ponders, for whom are copyright laws written.

Building Science by Standing on the Shoulders of Giants

Director of Technology for Sage Bionetworks Michael Kellen gives context to the Synapse software. Kellen emphasizes that science is built by people working together.

Sage's Commitment to Tapping into Crowdsourced Research

Jonathan Derry, Director of Research for Sage Bionetworks, talks about Sage's campaign to utilize crowdsourced research.

Lifestyle Factors of People with Exceptional Longevity

George Church, PhD at Harvard Medical School, discusses how lifestyle factors of people with exceptional longevity differ from the rest of us.

Citizen Competitions: Building an Information Commons

Adam Margolin, Director of Computational Biology for Sage Bionetworks, discusses Sage's commitment to building community data networks through open citizen competition.

About this conference


2012 will be the third Commons Congress. Sage Bionetworks is in its fourth year and is deep into the transition from non-profit start-up to a provider of fundamental new infrastructure for network biology. The first part of the Congress will focus on this transition and the progress to date on how early investments in technical and legal data sharing platforms are beginning to pay off in faster science, increased patient engagement, and disruptive projects that can shake up the entire pharmaceutical industry. The second part will review activities and opportunities in ongoing pilots and projects. The third part will highlight emerging projects designed to shift sharing behaviors in drug development (Arch2POCM) and in disrupting the current medical-industrial social value chain.  The concluding part four will be a community effort to look at what is required to move beyond the current medical information system and its rewards.

About Sage Bionetworks


Sage Bionetworks was formed as a strategic nonprofit research organization with a mission to coordinate and link academic and commercial biomedical researchers through a Commons that represents a new paradigm for genomics intellectual property, researcher cooperation, and contributor-evolved resources.

We are located on the campus of the Fred Hutchinson Cancer Research Center in Seattle, Washington and are supported through a portfolio of philanthropic donations, competitive research grants, and commercial partnerships.


For more information, visit: http://sagebase.org/